EBR Systems (ASX:EBR) passed the tenth commercial implant of the WiSE System in the US during its pilot launch phase, according to a Wednesday filing with the Australian bourse.
The WiSE cardiac resynchronization therapy system delivers wireless cardiac pacing for heart failure.
The limited market release for the device is on track to begin in October, the filing said.
Shares rose 12% in midday trade on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.